| 31/01/23 | Sweet new tests not yet enough to improve revenue | Bell Potter Securities |
| 12/08/22 | Spending to secure the future | Bell Potter Securities |
| 11/08/22 | 1H22 result miss on revenue, EBITDA | Canaccord Genuity |
| 11/08/22 | Still loading the bases | Petra Capital |
| 22/06/22 | FY21 AGM – trading update notes delays in Sentia testing rollout | Canaccord Genuity |
| 22/06/22 | Still going to plan despite some delays | Petra Capital |
| 03/05/22 | Strong first quarter | Bell Potter Securities |
| 02/05/22 | Mar’Q report in line – 40% revenue growth qoq | Canaccord Genuity |
| 22/04/22 | Tn Antigen interim results positive; $26m capital raise announced | Sequoia Financial Group |
| 22/04/22 | Cashing up for an oncology market ascent | Petra Capital |
| 12/04/22 | Initiation – The future of biosensors | Bell Potter Securities |
| 30/03/22 | Initiation – Sensing the turnaround, with blue-sky potential | Canaccord Genuity |
| 17/03/22 | CY21 Results – Numerous product & development milestones expected | Sequoia Financial Group |
| 25/02/22 | Another big year ahead | Petra Capital |
| 31/01/22 | Weaker-than-expected 4Q21 sales | Petra Capital |
| 29/10/21 | Q3 Report – YTD Revenue up 277%; R&D investment steps up | Sequoia Financial Group |
| 26/10/21 | Sentia surpasses the $1m sales mark | Petra Capital |
| 10/08/21 | Interims provide confidence; Exciting product development pipeline | Sequoia Financial Group |
| 09/08/21 | Strong 1H21 revenue growth off a low base | Petra Capital |
| 01/07/21 | Buy signals are getting clearer | Petra Capital |
| 11/06/21 | Sentia Wine Analyser – Early feedback from Winemakers | Sequoia Financial Group |
| 09/06/21 | Worth every Sentia | Petra Capital |
| 19/05/21 | Initiation – Strong IP, New CEO, New Products, New Opportunities | Sequoia Financial Group |
| 06/05/21 | Initiation – Sensing a significant opportunity | Petra Capital |
